Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Université de Sherbrooke

$814,726.00

Precision virotherapy to treat bladder cancer

FY 2023-24

Summary
Cells in the bladder sometimes grow abnormally and lead to bladder cancer. Most often, these cancer cells remain in the bladder and are called nonmuscle invasive disease. Usually, these cancer cells are surgically removed from the bladder and the patient is treated with Bacillus Calmette Guerin (BCG) bacterial therapy to prevent cancer spread. However, many patients do not respond to BCG, develop toxic side effects, and require bladder removal to reduce their chances of dying from cancer spread. We will develop a new immunotherapy based on beneficial viruses called oncolytic viruses that only kills bladder cancer cells to prevent cancer spread. We have created a panel of viruses from which we will select the best one that we will test in animal models and ultimately use to eliminate bladder cancers in patients that fail BCG treatment.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
500513
Name
Tai Lee-Hwa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Precision virotherapy to treat bladder cancer
Programtype2
Operating Grants
Orgnameinp2
Université de Sherbrooke
Cihramount2
$814,726
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Bcg Failure; Bladder Cancer; Bladder-Sparing Therapy; Cytokines; Immunomodulation; Immunotherapy; Mouse Models; Translational Research; Tumor Immune Microenvironment; Virotherapy
Abstract
Cells in the bladder sometimes grow abnormally and lead to bladder cancer. Most often, these cancer cells remain in the bladder and are called nonmuscle invasive disease. Usually, these cancer cells are surgically removed from the bladder and the patient is treated with Bacillus Calmette Guerin (BCG) bacterial therapy to prevent cancer spread. However, many patients do not respond to BCG, develop toxic side effects, and require bladder removal to reduce their chances of dying from cancer spread. We will develop a new immunotherapy based on beneficial viruses called oncolytic viruses that only kills bladder cancer cells to prevent cancer spread. We have created a panel of viruses from which we will select the best one that we will test in animal models and ultimately use to eliminate bladder cancers in patients that fail BCG treatment.
Competitiondate
202403
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Tai, Lee-Hwa
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $814,726~ $0~